- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01851941
A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer
May 8, 2013 updated by: Seock-Ah Im, Seoul National University Hospital
The role of perioperative chemotherapy in potentially operable advanced gastric cancer (AGC) with regional lymph node metastasis is still in the area of controversy.
The aim of this study is to evaluate the efficacy and toxicity of folinic acid (FA), infusional 5-fluorouracil (5-FU), and oxaliplatin (modified FOLFOX6) in potentially resectable AGC with regional lymph node (LN) metastasis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 110-744
- Seoul National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Previously untreated patients with pathologically proven advanced gastric adenocarcinoma with regional LN metastasis (clinical stage: cT2-4 and N+)
- At least one measurable regional lymph node metastasis according to the Response Evaluation Criteria in Solid Tumors (RECIST v. 1.0)
- age between 18 and 75 years
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
- no prior chemotherapy or radiotherapy
- adequate bone marrow, hepatic and renal function (absolute neutrophil count [ANC] ≥ 1.5ⅹ109/L, platelet count ≥ 100ⅹ109/L, total bilirubin ≤ 1.5ⅹupper limit of normal [ULN], serum transaminases ≤ 2.5ⅹULN, alkaline phosphatase ≤ 2.5ⅹULN, serum creatinine ≤ 1.5ⅹULN or actual or calculated creatinine clearance ≥ 50 mL/min).
Exclusion Criteria:
- clinical stage T1 tumors
- clinical or radiologic evidence of distant metastasis
- intestinal obstruction or impending obstruction
- active tumor bleeding
- interstitial pneumonitis or symptomatic pulmonary fibrosis
- peripheral neuropathy of National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade ≥1
- pregnant or breastfeeding patients
- other serious diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: mFOLFOX6
Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks.
Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
|
Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks.
Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
clinical response rate as assessed using RECIST criteria, with computed tomography (CT) scans at baseline and after 4cycles of chemotherapy
Time Frame: 4 cycles of chemotherapy (expected average of 8 weeks)
|
4 cycles of chemotherapy (expected average of 8 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to progression
Time Frame: From date of study enrollment until the date of first documented progression, assessed up to 60 months
|
From date of study enrollment until the date of first documented progression, assessed up to 60 months
|
overall survival
Time Frame: From date of study enrollment until the date of first documented progression, assessed up to 60 months
|
From date of study enrollment until the date of first documented progression, assessed up to 60 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
gene expression profile
Time Frame: after 4 cycles of chemotherapy (expected average of 8 weeks)
|
after 4 cycles of chemotherapy (expected average of 8 weeks)
|
early metabolic response by PET-CT
Time Frame: 2 cycles of chemotherapy (expected average of 4 weeks)
|
2 cycles of chemotherapy (expected average of 4 weeks)
|
Pharmacologic Genetic Marker
Time Frame: 4 cycles of chemotherapy (expected average of 8 weeks)
|
4 cycles of chemotherapy (expected average of 8 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2004
Primary Completion (ACTUAL)
June 1, 2008
Study Registration Dates
First Submitted
May 6, 2013
First Submitted That Met QC Criteria
May 8, 2013
First Posted (ESTIMATE)
May 13, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
May 13, 2013
Last Update Submitted That Met QC Criteria
May 8, 2013
Last Verified
May 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Stomach Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Micronutrients
- Vitamins
- Antidotes
- Vitamin B Complex
- Hematinics
- Fluorouracil
- Oxaliplatin
- Leucovorin
- Levoleucovorin
- Folic Acid
Other Study ID Numbers
- H 0406127 007 (OTHER: Seoul National University Hospital)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Gastric Cancer
-
GeneScience Pharmaceuticals Co., Ltd.The First Affiliated Hospital with Nanjing Medical University; Tongji Hospital and other collaboratorsUnknownAdvanced Gastric or Gastroesophageal Junction CancerChina
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
Ukrainian Society of Clinical OncologyRecruitingStomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastrointestinal Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | GastroEsophageal Cancer | Stomach Neoplasm | Gastric Neoplasm | Advanced Gastric Carcinoma | Advanced Gastroesophageal Junction AdenocarcinomaUkraine
-
Shanghai Miracogen Inc.RecruitingAdvanced Solid Tumors | Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction CancerUnited States
-
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.RecruitingAdvanced Breast Cancer | Advanced Solid Tumor | Advanced Gastric CancerUnited States
-
Krankenhaus NordwestCompletedAdvanced Gastric Cancer | Advanced Cancer of the Esophagogastric JunctionGermany
-
Huashan HospitalSeattle Integrative Cancer CenterUnknownMetastatic Gastric Cancer | Locally Advanced Gastric CancerChina, United States
-
Astellas Pharma Global Development, Inc.AvailableMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma CancerUnited States
-
Gruppo Italiano per lo studio dei Carcinomi dell...Regione LombardiaTerminatedMetastatic Gastric Cancer | Locally Advanced Unresectable Gastric CancerItaly
-
Krankenhaus NordwestCompletedAdvanced Gastric Cancer | Esophagogastric Junction CancerGermany
Clinical Trials on mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )
-
Suzhou Transcenta Therapeutics Co., Ltd.Not yet recruitingGastric Cancer | Advanced Cancer | Gastroesophageal-junction Cancer
-
The Nordic Colorectal Cancer Biomodulation GroupCompletedMetastatic Colorectal CancerNorway
-
AIO-Studien-gGmbHAmgen; ClinAssess GmbHCompleted
-
UNC Lineberger Comprehensive Cancer CenterCompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Metastatic Pancreatic CancerUnited States
-
National Cancer Centre, SingaporeNational Medical Research Council (NMRC), Singapore; ASLAN PharmaceuticalsActive, not recruiting
-
TG Therapeutics, Inc.SCRI Development Innovations, LLCCompletedGastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Gastrointestinal Stromal Tumor (GIST)United States
-
UNICANCERCompleted
-
GERCOR - Multidisciplinary Oncology Cooperative...CompletedColorectal Cancer | Chemotherapy | Metastatic CancerFrance
-
BayerCompletedColorectal NeoplasmsBelgium, Spain, Australia, Germany, United Kingdom, Italy, United States
-
Hoffmann-La RocheCompletedColorectal CancerUnited Kingdom